AtriCure Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de AtriCure de 7% y 12.7% por año respectivamente. Se prevé que el BPA crezca en un 9.6% al año. Se espera que la rentabilidad financiera sea de -3.2% en 3 años.

Información clave

7.0%

Tasa de crecimiento de los beneficios

9.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.1%
Tasa de crecimiento de los ingresos	12.7%
Rentabilidad financiera futura	-3.2%
Cobertura de analistas	Good
Última actualización	23 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08

Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 11

Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Feb 18

Why AtriCure, Inc. (NASDAQ:ATRC) Could Be Worth Watching

Jan 20

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:ATRC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	595	-20	41	60	7
12/31/2025	526	-27	17	33	9
12/31/2024	461	-34	N/A	14	9
12/31/2023	399	-30	-8	4	N/A
9/30/2023	381	-25	-13	1	N/A
6/30/2023	366	-28	-48	-3	N/A
3/31/2023	349	-38	-18	-2	N/A
12/31/2022	330	-46	-39	-22	N/A
9/30/2022	316	-56	-37	-22	N/A
6/30/2022	303	53	-32	-20	N/A
3/31/2022	290	52	-41	-29	N/A
12/31/2021	274	50	-24	-14	N/A
9/30/2021	259	45	-18	-10	N/A
6/30/2021	243	-57	-14	-6	N/A
3/31/2021	213	-49	-18	-13	N/A
12/31/2020	207	-48	-25	-20	N/A
9/30/2020	210	-46	-36	-27	N/A
6/30/2020	212	-50	-44	-34	N/A
3/31/2020	230	-46	-31	-18	N/A
12/31/2019	231	-35	-28	-16	N/A
9/30/2019	222	-23	-20	-11	N/A
6/30/2019	216	-20	-11	-3	N/A
3/31/2019	209	-17	-14	-8	N/A
12/31/2018	202	-21	-10	-4	N/A
9/30/2018	195	-20	-10	-4	N/A
6/30/2018	187	-20	-15	-9	N/A
3/31/2018	180	-27	-16	-9	N/A
12/31/2017	175	-27	-15	-9	N/A
9/30/2017	170	-33	N/A	-10	N/A
6/30/2017	166	-32	N/A	-9	N/A
3/31/2017	160	-34	N/A	-14	N/A
12/31/2016	155	-33	N/A	-15	N/A
9/30/2016	150	-36	N/A	-20	N/A
6/30/2016	143	-35	N/A	-18	N/A
3/31/2016	135	-32	N/A	-10	N/A
12/31/2015	129	-27	N/A	-8	N/A
9/30/2015	123	-22	N/A	-6	N/A
6/30/2015	118	-16	N/A	-10	N/A
3/31/2015	112	-14	N/A	-16	N/A
12/31/2014	107	-16	N/A	-22	N/A
9/30/2014	99	-16	N/A	-23	N/A
6/30/2014	93	-18	N/A	-21	N/A
3/31/2014	87	-17	N/A	-17	N/A
12/31/2013	81	-11	N/A	-5	N/A
9/30/2013	78	-9	N/A	-2	N/A
6/30/2013	74	-8	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ATRC siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ATRC siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ATRC siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (12.7% al año) de ATRC crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12.7% al año) de ATRC crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: ATRC se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

AtriCure Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Atricure, Inc. Provides Earnings Guidance for 2024

Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.70 loss

AtriCure, Inc. Provides Revenue Guidance for the 2023

Recent updates

AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management

AtriCure, Inc. to Report Q1, 2024 Results on May 01, 2024

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

AtriCure, Inc., Annual General Meeting, May 13, 2024

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board’s Strategy Committee and Compliance, Quality and Risk Committee

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Atricure, Inc. Provides Earnings Guidance for 2024

AtriCure, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Consensus EPS estimates upgraded to US$0.70 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AtriCure, Inc. Provides Revenue Guidance for the 2023

AtriCure, Inc. to Report Q3, 2023 Results on Nov 01, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Now 24% undervalued

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Consensus estimates of losses per share improve by 15%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Atricure, Inc. Provides Revenue Guidance for the Year 2023

AtriCure, Inc. to Report Q2, 2023 Results on Jul 25, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Independent Director recently sold US$203k worth of stock

Independent Director notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Provides Revenue Guidance for Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Independent Director exercised options to buy US$393k worth of stock.

Now 21% undervalued after recent price drop

Independent Director exercised options to buy US$799k worth of stock.

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Consensus EPS estimates fall by 31%

Price target decreased by 7.7% to US$56.33

Full year 2022 earnings: EPS exceeds analyst expectations

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

AtriCure, Inc. Announces the First Patient Treated in the LeAAPS™ Clinical Trial

AtriCure, Inc. to Report Q4, 2022 Results on Feb 21, 2023

AtriCure, Inc. Provides Earnings Guidance for 2023

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Now 21% undervalued

Price target decreased to US$57.83

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

AtriCure, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Chief Scientific Officer recently sold US$229k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Independent Director exercised options to buy US$642k worth of stock.

Insider notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Insider notifies of intention to sell stock

Price target decreased to US$69.50

AtriCure, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Price target decreased to US$74.83

Insider notifies of intention to sell stock

Investor sentiment deteriorated over the past week